Building Pharmaceutical Sovereignty in Africa
Establishing WHO Prequalification-aligned pharmaceutical manufacturing in Mozambique to serve 380 million people across the SADC region with essential medicines and supply chain resilience through WHO-aligned manufacturing.
Our Mission
Building pharmaceutical sovereignty in Africa through WHO-aligned manufacturing and supply resilience
WHO GMP Manufacturing
State-of-the-art sterile injectables facility built to World Health Organization Good Manufacturing Practice standards from day one.
Essential Medicines
7 WHO Essential Medicines with 21.6 million vials annual capacity, addressing critical healthcare needs across the SADC region.
Regional Impact
Serving 380 million people across 15 SADC countries, reducing pharmaceutical import dependency and improving healthcare access.
Addressing Africa's Pharmaceutical Challenge
The Problem
Sub-Saharan Africa imports 88% of its pharmaceuticals, creating:
- Supply chain vulnerabilities exposed by COVID-19
- 20-30% higher costs compared to local production
- Limited access to essential medicines
- Economic dependency and capital outflow
- Lack of pharmaceutical manufacturing capacity
Our Solution
AfriPharma is establishing Mozambique's first WHO PQ-aligned manufacturing facility:
- Local production of 7 WHO Essential Medicines
- WHO Prequalification pathway for international standards
- Strategic Nacala port location for SADC distribution
- 150+ high-skilled pharmaceutical manufacturing jobs
- $50M+ import substitution by Year 5
Why Mozambique & Nacala SEZ
Strategic location, government support, and regional gateway to 380M people
Deep-Water Port
Nacala's deep-water port provides direct access to SADC markets with efficient logistics for raw material imports and finished product exports.
SEZ Incentives
10-year corporate tax exemption, import duty waivers on equipment and raw materials, simplified customs procedures, and dedicated infrastructure support.
Government Support
Strong commitment from Mozambique government to pharmaceutical manufacturing, alignment with national industrialization strategy, and WHO collaboration.
Regional Gateway
Strategic access to Tanzania, Malawi, Zambia, and broader SADC region. Growing $3.2B pharmaceutical market with 8-12% annual growth.
Our Journey
From vision to commercial production
2024 - Foundation & Fundraising
Q4 2025: Corporate structure formalization, investor outreach, November Mozambique site visit, regulatory pathway planning
2025 - Regulatory Approvals
Q3-Q4: MISAU pharmaceutical license application, SEZ agreement finalization, WHO PQ pathway initiation, product development studies
2026 - Facility Construction
Full Year: WHO GMP-compliant facility construction, equipment installation, staff recruitment and training, quality systems development
2027 - Commercial Launch
Q1: Commissioning and validation | Q2: First production runs | Q3-Q4: Commercial production and market launch
Join Us in Building Pharmaceutical Sovereignty
We're raising $12M to establish Africa's pharmaceutical future. Partner with us to create measurable impact across healthcare access, job creation, and economic development.